A Case of Hydroxyurea-Induced Cutaneous Ulceration and Squamous Cell Carcinoma.
- Author:
Sook Jung YUN
1
;
Jee Bum LEE
;
Seong Jin KIM
;
Seung Chul LEE
;
Young Ho WON
Author Information
1. Department of Dermatology, Chonnam National University Medical School, Gwangju, Korea. yhwon@chonnam.ac.kr
- Publication Type:Case Report
- Keywords:
Hydroxyurea;
CML;
Ulceration;
Squamous cell carcinoma
- MeSH:
Aged;
Alopecia;
Atrophy;
Carcinoma, Squamous Cell*;
Dermatomyositis;
DNA;
Drug Therapy;
Erythema;
Female;
Humans;
Hydroxyurea;
Hyperpigmentation;
Korea;
Lichens;
Polycythemia Vera;
Ribonucleotide Reductases;
Skin;
Subcutaneous Tissue;
Ulcer*
- From:Korean Journal of Dermatology
2002;40(4):433-436
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Hydroxyurea, one of conventional chemotherapies in chronic myelogenous leukemia(CML) and polycythemia vera, inhibits ribonucleotide reductase, which catalyzes the rate-limiting step in the de novo synthesis of deoxynucleotide triphosphates required for DNA synthesis. Various cutaneous side effects due to hydroxyurea have been reported as follows; alopecia, diffuse hyperpigmentation, scaling, poikiloderma, atrophy of the skin and subcutaneous tissues, nail changes with multiple pigmented nail bands or brittleness, erythema and scaling of acral sites simulating chronic dermatomyositis, lichen planus-like lesions, or skin tumors on the UV-light exposed areas.A 72-year-old woman, receiving hydroxyurea for CML during 5 years, revealed hydroxyurea dermopathy such as scaly papules, poikilodermatous patches, and acral ulceration, and unusually developed squamous cell carcinoma. This is a rare case of hydroxyurea dermopathy and the first case of squamous cell carcinoma by hydroxyurea in Korea.
